New Medication Release of Symbravo

The FDA recently approved Symbravo® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults. Symbravo® is not indicated for the preventative treatment of migraine, or for the treatment of cluster headaches.

Symbravo® tablets are manufactured by Axsome Therapeutics and contain 20 mg of meloxicam, a nonsteroidal anti-inflammatory drug (NSAID), and 1 0mg of rizatriptan, a selective 5-HT receptor agonist, per tablet.

Symbravo® is a brand name combination medication composed of two active ingredients that are available separately in generic formulations. Typically, the cost of combination medications is higher than single ingredient medications.

For more information on Symbravo, or to see full prescribing information, including boxed warning for risk of serious cardiovascular and gastrointestinal adverse events, visit https://www.symbravo.com.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.